OBJECTIVE: To present an effective approach to the early detection of lethal prostate cancer using longitudinal data on prostate-specific antigen (PSA) and its rate of change, i.e. PSA velocity (PSAV). This longitudinal approach might also be extendible to other biomarkers. SUBJECTS AND METHODS: PSAV was calculated using five techniques for 634 subjects with at least three PSA measurements in a longitudinal ageing study, censoring PSA levels of > 10 ng/mL. The efficacy for predicting death from prostate cancer was assessed with concordance indices and by using net reclassification improvement (NRI), which indicated the net increase in sensitivity and specificity when adding a biomarker to a base Cox proportional hazards model. The PSAV techniques were compared for the 5-10 years before the clinical diagnosis of prostate cancer. The most effective technique was then applied at the transition point when each man's PSA history curve transformed from linear to exponentially increasing, and its predictive value was compared to that of concurrent PSA level. RESULTS: A PSA transition point was found in 522 (82%) of the 634 men, including all 11 who died from prostate cancer. At the transition point, the mean PSA level was 1.4 ng/mL, and PSAV but not PSA level was significantly higher among men who died from prostate cancer than among men who did not (P = 0.021 vs P = 0.112; Wilcoxon two-sample test). At the transition point, adding PSAV to a base model consisting of age and date of diagnosis improved the concordance index by 0.05, and significantly improved the overall sensitivity and specificity (NRI, P = 0.028), while adding PSA level to the same base model resulted in little improvement (concordance index increase < 0.01 and NRI P = 0.275). CONCLUSION: When the shape of a man's PSA history curve changes from linear to exponential, PSAV might help in the early identification of life-threatening prostate cancer at a time when PSA values are still low in most men.
OBJECTIVE: To present an effective approach to the early detection of lethal prostate cancer using longitudinal data on prostate-specific antigen (PSA) and its rate of change, i.e. PSA velocity (PSAV). This longitudinal approach might also be extendible to other biomarkers. SUBJECTS AND METHODS: PSAV was calculated using five techniques for 634 subjects with at least three PSA measurements in a longitudinal ageing study, censoring PSA levels of > 10 ng/mL. The efficacy for predicting death from prostate cancer was assessed with concordance indices and by using net reclassification improvement (NRI), which indicated the net increase in sensitivity and specificity when adding a biomarker to a base Cox proportional hazards model. The PSAV techniques were compared for the 5-10 years before the clinical diagnosis of prostate cancer. The most effective technique was then applied at the transition point when each man's PSA history curve transformed from linear to exponentially increasing, and its predictive value was compared to that of concurrent PSA level. RESULTS: A PSA transition point was found in 522 (82%) of the 634 men, including all 11 who died from prostate cancer. At the transition point, the mean PSA level was 1.4 ng/mL, and PSAV but not PSA level was significantly higher among men who died from prostate cancer than among men who did not (P = 0.021 vs P = 0.112; Wilcoxon two-sample test). At the transition point, adding PSAV to a base model consisting of age and date of diagnosis improved the concordance index by 0.05, and significantly improved the overall sensitivity and specificity (NRI, P = 0.028), while adding PSA level to the same base model resulted in little improvement (concordance index increase < 0.01 and NRI P = 0.275). CONCLUSION: When the shape of a man's PSA history curve changes from linear to exponential, PSAV might help in the early identification of life-threatening prostate cancer at a time when PSA values are still low in most men.
Authors: Shomik Sengupta; Robert P Myers; Jeffrey M Slezak; Eric J Bergstralh; Horst Zincke; Michael L Blute Journal: J Urol Date: 2005-12 Impact factor: 7.450
Authors: Fritz H Schröder; Monique J Roobol; Theo H van der Kwast; Ries Kranse; Chris H Bangma Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter Journal: J Natl Cancer Inst Date: 2006-11-01 Impact factor: 13.506
Authors: Lurdes Y T Inoue; Ruth Etzioni; Elizabeth H Slate; Christopher Morrell; David F Penson Journal: Biostatistics Date: 2004-07 Impact factor: 5.899
Authors: H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh Journal: JAMA Date: 1992 Apr 22-29 Impact factor: 56.272
Authors: Andrew J Vickers; Tineke Wolters; Caroline J Savage; Angel M Cronin; M Frank O'Brien; Kim Pettersson; Monique J Roobol; Gunnar Aus; Peter T Scardino; Jonas Hugosson; Fritz H Schröder; Hans Lilja Journal: Eur Urol Date: 2009-08-07 Impact factor: 20.096
Authors: Hiten D Patel; Zhaoyong Feng; Patricia Landis; Bruce J Trock; Jonathan I Epstein; H Ballentine Carter Journal: J Urol Date: 2013-09-20 Impact factor: 7.450
Authors: R Jeffrey Karnes; F Roy MacKintosh; Christopher H Morrell; Lori Rawson; Preston C Sprenkle; Michael W Kattan; Michele Colicchia; Thomas B Neville Journal: Front Oncol Date: 2018-08-06 Impact factor: 6.244
Authors: David Margel; David R Urbach; Lorraine L Lipscombe; Chaim M Bell; Girish Kulkarni; Jack Baniel; Neil Fleshner; Peter C Austin Journal: BMC Med Inform Decis Mak Date: 2014-12-12 Impact factor: 2.796